Guillermo Ojeda

Targeting cytokine and chemokine signaling pathways for cancer therapy

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest

Efficacy and safety of once‐daily maraviroc plus ritonavir‐boosted darunavir in pretreated HIV‐infected patients in a real‐life setting

Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy